AEON Biopharma Announces Clinical Update And Productive End-Of-Phase 2 Meeting With FDA On ABP-450 For Preventive Treatment Of Migraine

Benzinga · Mar 20 04:31

– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –

– An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are expected in Q2 2024; previously stated timeline for top-line data on the complete cohort remains on track for Q3 2024 –

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

AEON Biopharma Announces Clinical Update And Productive End-Of-Phase 2 Meeting With FDA On ABP-450 For Preventive Treatment Of Migraine

Risk Disclaimer